European Pharmaceutical Review

JANUARY 4, 2023

“Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” stated Dr Flavius Martin, Executive Vice President, Research at Gilead. “We EVOQ’s NanoDisc technology for rheumatoid arthritis and lupus.

Immunization 95

Immunization 95

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences research executive vice-president Flavius Martin stated: “The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases.

Immunization 52

Immunization 52

European Pharmaceutical Review

JANUARY 4, 2023

“Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” stated Dr Flavius Martin, Executive Vice President, Research at Gilead. “We EVOQ’s NanoDisc technology for rheumatoid arthritis and lupus.

Immunization 52

Immunization 52

Pharmaceutical Technology

JANUARY 4, 2023

Gilead Research executive vice-president Flavius Martin said: “Despite key advances over the past two decades, there remains a significant unmet need for people living with inflammatory and autoimmune diseases. “We The company will also receive tiered royalties on sales of the product.

Immunization 52

Immunization 52

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences Research executive vice-president Flavius Martin said: “The Nurix IRAK4 degrader programme represents a quality modality targeting toll-like receptor and IL1 receptor-driven inflammation. “We

52

52

pharmaphorum

JANUARY 4, 2023

“Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” said Flavius Martin, Gilead’s head of research.

Immunization 52

Immunization 52

ISPE

SEPTEMBER 8, 2023

Research Panel I get the privilege of moderating a panel with Flavius Martin, who heads up worldwide research for Gilead Sciences, and I know he will share an interesting perspective on how, as a profession, we can add more value to the overall scientific ambitions within the industry.

52

52